Biogen, Ionis Launch $1B+ Expanded Neuro Drug Partnership, following Spinraza Success

Six years after they began partnering to successfully develop the spinal muscular atrophy (SMA) treatment Spinraza ® (nusinersen), Biogen and Ionis Pharmaceuticals said today they have launched a 10-year, $1 billion-plus expanded collaboration to develop more neurological drugs.The companies said they plan to develop novel antisense drug candidates for a broad range of neurological diseases for which few treatments now exist. The indications include dementia, neuromuscular diseases, movement